DXR

DAXOR CORP 10-Q Summary: Quarter Ended June 30, 2005

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2005, and the six months ended June 30, 2005. Daxor Corporation is a medical device manufacturer focused on the Blood Volume Analyzer (BVA-100) and related diagnostic kits, alongside biotech services including cryobanking of blood and semen. The company operates three segments: Equipment Sales and Related Services, Cryobanking and Related Services, and Investment Portfolio Activity. The financial statements for the prior year (2004) have been restated to reflect a change in revenue recognition policy regarding deferred storage fees.

Key Financial Metrics

Segment Performance (Six Months 2005):

• Equipment Sales: Revenue of $336,396; Segment Loss of $(2,413,065).
• Cryobanking: Revenue of $220,176; Segment Loss of $(25,277).
• Investment Portfolio: Income of $1,130,456 (primarily dividends and gains); Segment Income of $995,567.

Material Changes vs. Prior Period

• Operating Revenue: Increased 11% to $556,572 for the six months ended June 30, 2005, driven primarily by increased sales of blood volume kits.
• Operating Loss: Widened significantly to $(2,447,257) from $(1,741,795) in the prior year period. Total costs and expenses rose 34% to $3,003,829 due to increased marketing efforts and R&D expenses.
• Investment Income: Total other income decreased 25% to $1,004,482. While dividend income increased to $1,048,696, realized gains on the sale of securities dropped to $81,760 from $426,696 in the prior year.
• Liquidity: Cash and cash equivalents depleted to $0 from $5,079 at year-end 2004. The company utilized cash for operating activities and net purchases of investments.
• Debt: Loans payable increased to $6,543,041, consisting of a $1.5 million bank note and $5.04 million in short-term margin debt secured by marketable securities.

Guidance, Outlook, and Risks

Management Commentary: Management reports no sales of the BVA-100 Blood Volume Analyzer equipment in 2005, though trial contracts were signed. A primary factor hindering sales was a delay in Medicare reimbursement for the radiopharmaceutical kits. The reimbursement number was issued in July 2005, effective January 2006. Management plans to expand the sales force (currently 17 salesmen) and support staff. The company anticipates that BVA-100 sales and kits will become the major income source once reimbursement issues are resolved.

Risks and Contingencies:

• Reimbursement Risk: Sales are contingent on Medicare reimbursement corrections effective January 2006.
• Liquidity Risk: Operating cash flow is negative, and the company relies heavily on investment portfolio income to offset operating losses. Cash on hand is currently $0.
• Market Risk: The investment portfolio (primarily utility stocks) is exposed to interest rate fluctuations and regulatory changes. Two bonds in the portfolio are in default, valued at zero.
• Concentration Risk: The largest portfolio holding is Entergy stock, representing 16.92% of the portfolio value.

Investor Verification Checklist

• Cash Position: Verify the sustainability of operations with $0 cash on hand and negative operating cash flow.
• Medicare Reimbursement: Confirm the impact of the January 2006 effective date for kit reimbursement on future revenue projections.
• Debt Covenants: Review terms of the $6.5 million in loans payable, specifically the margin debt secured by the investment portfolio.
• Investment Portfolio Valuation: Assess the risk of the two defaulted bonds and the concentration in utility stocks.
• Restatement Impact: Understand the full effect of the 2004 revenue recognition restatement on year-over-year comparisons.